Dr Ahn on Phase 2a Data With Atebimetinib and Chemotherapy in Pancreatic Cancer

Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel Shows Encouraging Efficacy, Tolerability in First-Line Metastatic PDAC

Uprising in pancreatic space more than Revolution

ASCO 2026: Immuneering presented an update of the P2 trial of its deep cyclic inhibitor of MEK in 1L pancreatic cancer at ASCO. CEO Ben Zeskind argues why competitor data should not overshadow this

ASCO: Biopharma has pancreatic cancer ‘surrounded’ as Immuneering’s drug adds 9 quality months

ASCO to spotlight pancreatic cancer innovation beyond KRAS

MEK inhibitor delivers 17.3-month OS for pancreatic cancer

Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes

How Immuneering’s Journey Highlights the Biotech Markets Complexity, with CEO Ben Zeskind

Outsmarting resistance with rhythm